13F Holdings
中文EN

AXGN Axogen, Inc.

Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 805928 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY24.3%
TTM net income YoY-1,422.3%
TTM EPS YoY-1,160.0%
Revenue 3-yr CAGR20.6%
Net income 3-yr CAGR—

Margins

Gross margin74.2%
Operating margin-5.2%
Net margin-12.0%
FCF margin8.3%
EBITDA margin-2.8%

Returns

ROE-10.3%
ROA-8.3%
ROIC (approx.)-7.1%
Asset turnover0.70x

Leverage & solvency

Liabilities / assets9.9%
Debt / equity0.00x
Current ratio12.02x
Interest coverage-5.72x

Cash quality & payout

Operating cash flow / net income-0.89x
Accruals ratio-15.7%
Payout ratio—
Capex / revenue2.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$225.21M$187.34M$159.01M$138.58M$127.36M
Cost of revenue$57.85M$45.36M$37.14M$29.77M$22.93M
Gross profit$167.35M$141.98M$121.87M$108.81M$104.43M
R&D expense$32.88M$27.77M$27.34M$25.63M$24.18M
SG&A expense$44.58M$39.04M$38.41M$40.91M$32.34M
Operating income-$7.85M-$3.29M-$21.46M-$29.71M-$25.42M
Interest expense$7.70M$8.21M$2.83M$624,000$1.36M
Income tax$0$0$0$0$0
Net income-$15.70M-$9.96M-$21.72M-$28.95M-$26.98M
EBITDA-$1.19M$3.18M-$17.24M-$26.88M-$22.67M
EPS (basic)-0.34-0.23-0.51-0.69-0.65
EPS (diluted)-0.34-0.23-0.51-0.69-0.65
Weighted avg. shares (diluted)46.05M44.26M42.88M42.08M41.21M
Balance sheet
Cash & equivalents$35.55M$33.55M$37.03M$21.54M$39.01M
Short-term investments$5.98M$5.93M$0$33.51M$51.33M
Receivables$26.17M$24.11M$25.15M$22.19M$18.16M
Inventory$42.37M$33.18M$23.02M$18.91M$16.69M
Current assets$120.42M$99.22M$88.00M$98.08M$127.05M
PP&E, net$81.78M$84.67M$88.73M$79.29M$62.92M
Intangibles$6.75M$5.58M$4.53M$3.65M$2.86M
Total assets$221.69M$203.73M$196.83M$195.39M$208.02M
Current liabilities$23.56M$30.61M$30.43M$23.75M$24.29M
Long-term debt$48.39M$47.50M$46.60M$45.71M$44.82M
Total debt$48.39M$47.50M$46.60M$45.71M$44.82M
Total liabilities$92.84M$99.82M$101.16M$94.39M$95.47M
Shareholders' equity$128.85M$103.91M$95.67M$101.00M$112.55M
Net debt$12.84M$13.94M$9.58M$24.18M$5.81M
Shares outstanding47.20M44.15M43.12M42.45M41.74M
Cash flow statement
Operating cash flow$812,000$4.54M-$5.72M-$16.07M-$13.40M
Capital expenditure$3.75M$3.10M$13.87M$20.08M$27.81M
Free cash flow-$2.93M$1.43M-$19.59M-$36.14M-$41.22M
Investing cash flow-$5.32M-$10.30M$19.25M-$3.20M-$23.65M
Financing cash flow$10.50M$2.29M$1.95M$1.79M$20.45M
Depreciation & amortization$6.66M$6.47M$4.22M$2.83M$2.74M
Stock-based compensation$30.11M$15.91M$14.42M$15.59M$10.92M

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.